e-learning
resources
Conferences
Respiratory Failure and Mechanical Ventilation Conference 2020
2020
Friday, 14.02.2020
Paediatrics and Quality of life
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of the phosphatidylcholine treatment program on the respiratory failure in patients with community-acquired pneumonia
O. Shtepa (Dnipro, Ukraine)
Source:
Respiratory Failure and Mechanical Ventilation Conference 2020
Session:
Paediatrics and Quality of life
Session type:
Poster Discussion
Number:
128
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Shtepa (Dnipro, Ukraine). Impact of the phosphatidylcholine treatment program on the respiratory failure in patients with community-acquired pneumonia. Respiratory Failure and Mechanical Ventilation Conference 2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Cost of treatment failure in community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 195s
Year: 2007
Community-acquired pneumonia as a cause of acute respiratory failure (ARF) in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 518s
Year: 2005
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 42s
Year: 2007
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Lower respiratory tract infections: when are antibiotics mandatory?
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146
Year: 2004
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Prevention of nosocomial infections in acute respiratory failure patients
Source: Eur Respir J 2003; 22: 72S-76S
Year: 2003
Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 106s
Year: 2006
Treatment failure of severe and ventilator-associated pneumonia
Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections
Year: 2012
Characteristics of pnemococcal community-acquired pneumonia presenting with respiratory failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
Impact of nosocomial pneumonia on the outcome of mechanically-ventilated patients
Source: Eur Respir J 2004; 24: Suppl. 48, 548s
Year: 2004
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Mixed community-acquired pneumonia in hospitalised patients
Source: Eur Respir J 2006; 27: 795-800
Year: 2006
The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Clinical failure in community-acquired pneumonia
Source: International Congress 2014 – PG16 Low respiratory tract infections: learning from real clinical cases
Year: 2014
Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression
Source: Eur Respir J 2012; 40: 1201-1210
Year: 2012
Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept